Navigation Links
Vicor Technologies announces results of PD2i analysis of MUSIC trial data
Date:5/19/2010

Boca Raton, FL May 19, 2010 David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca (MUSIC) Trial using its PD2i algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i nonlinear algorithm and software. Vicor develops diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

The study, titled "Prognostic Significance of Point Correlation Dimension Algorithm (PD2i) in Chronic Heart Failure," was conducted under a collaborative agreement with the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona. The goal of the study was to evaluate the ability of Vicor's PD2i nonlinear algorithm to predict cardiac events in the 537 chronic heart failure patients enrolled in the MUSIC Trial; MUSIC Trial participants were followed for an average period of 44 months. The conclusion of the University of Rochester researchers who conducted the study is that the PD2i nonlinear algorithm and software is predictive of total mortality, cardiac death, and heart failure death in patients with left ventricular ejection fraction of less than or equal to 35%. With a P value of 0.004 the study results are highly statistically significant.

Commenting on the study and its results, Wojciech Zareba, M.D. Ph.D. the Principal Investigator at the University of Rochester said, "These results are of major importance for risk stratifying heart failure patients who are eligible for therapy with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D). Currently, only about 30-40% of heart failure patients eligible for this therapy receive devices. Testing heart failure patients using the PD2i should enhance risk stratification and motivate physicians to implant these devices in ICD/CRT-D eligible patients with abnormal PD2i test results."

"We're extremely pleased with the results achieved in this study. Researchers from the University of Rochester and Vicor scientists are studying these initial results to determine whether the resulting data will support a 510(k) submission to the Food and Drug Administration (FDA) for a marketing claim. What we have achieved may broaden the market for the PD2i Analyzer as a diagnostic that will significantly contribute to cardiologists in their assessment of treatment options for heart failure patients," stated Mr. Fater.


'/>"/>

Contact: Robin Schoen
schoenpr@comcast.net
215-504-2122
Vicor Technologies, Inc.
Source:Eurekalert

Related biology news :

1. NIH awards UC $9 million grant to improve patient point-of-care technologies
2. Patent Issued for e-Smart Technologies, Inc.s First Biometric Match-on-Card Technology
3. Titanium Group to Showcase Products and Technologies in Prestigious Government Seminar
4. e-Smart Technologies Responds to Press Release Issued By IDsmart LLC
5. e-Smart Technologies, Inc. Responds to Information Subpoenas From Securities & Exchange Commission
6. e-Smart(R) Technologies, Inc., Announces Next Generation Superthin Polyimide Flexible Circuit Biometric Super Smart Card(TM) card, the i am(TM) Card.
7. Material Technologies Holds First Electrochemical Fatigue Sensor Training for Private Inspection Firms
8. e-Smart(R) Technologies Delivers Its New Super Smart Card(TM) in South Korea.
9. e-SMART Technologies Continues Delivery of Its New Super SMART Card in South Korea
10. Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs
11. Atmel and Phoenix Technologies Collaborate to Create Next-generation Security Solutions for PCs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... RALEIGH, N.C. , Dec. 6, 2016 ... technology, announced today it has seen a third consecutive ... biometric sensor technology in 2016 with a 360 ... over last year. This increase was driven by sales ... well as robust interest in its technology for hearables ...
(Date:12/5/2016)... -- The Office of Justice Programs, National Institute of ... or Replace Medico Legal Autopsies?" on NIJ.gov.  The ... forensic autopsies with postmortem X-ray computed tomography, commonly ... to recommendations made by The National Academy of ... a potential component of medicolegal death investigations. NIJ,s ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable devices ... taking over sports. On Thursday, December 15th a panel of entrepreneurs, innovators and ... playing field at a Smart Talk session. Smart Talk will run from 8:30 ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...
Breaking Biology Technology: